September 26, 2011

Warnex Bioanalytical Services Receives DEQAS Certification for Vitamin D Analysis

Laval, Quebec, September 26, 2011 - Warnex Inc. (TSX: WNX) announced today that its Bioanalytical Services division participated in the international External Quality Assessment Scheme (DEQAS) and has received certification from DEQAS for the analysis of vitamin D (25-hydroxyvitamin D).

"With the increased attention on health issues related to vitamin D, the demand for vitamin D testing has risen dramatically in the past few years," said Mark Busgang, President and CEO of Warnex. "Warnex provides a highly accurate method for the detection of vitamin D. We are pleased to obtain this certification, which demonstrates our continued commitment to providing quality science and results to our customers".

The analysis of 25-hydroxyvitamin D is one of the most accurate ways to determine the level of vitamin D in the body. Warnex uses high performance liquid chromatography (HPLC) combined with mass spectrometry (MS/MS) to measure 25-hydroxyvitamin D2 and D3 in human blood plasma.

By participating in DEQAS, Warnex demonstrated that its HPLC/MS/MS method is reliable with respect to absolute values, assay linearity, as well as assay precision, and can be used with confidence by clinicians to assess vitamin D deficiency in patients.

Vitamin D deficiency, which results from inadequate nutritional intake of vitamin D and inadequate sunlight exposure, leads to bone softening diseases such as rickets in children and osteomalacia and osteoporosis in adults. Vitamin D has also been linked to many other conditions, including certain cancers, type 1 diabetes, multiple sclerosis, tuberculosis, Alzheimer's disease, psoriasis, and all-cause mortality.

About Warnex

Warnex ( is a life sciences company devoted to protecting public health by providing laboratory services to the pharmaceutical and healthcare sectors. Warnex Analytical Services provides pharmaceutical and biotechnology companies with a variety of quality control services, including chemistry, chromatography, microbiology, method development and validation, and stability studies. Warnex Bioanalytical Services specializes in bioequivalence and bioavailability studies for clinical trials. Warnex Medical Laboratories provides specialized testing for the healthcare industry as well as pharmaceutical and central laboratory services. Warnex PRO-DNA Services offers DNA identification tests for paternity, maternity and other family relationships, as well as for immigration and forensic testing purposes. Warnex has three facilities located in Laval and Blainville, Quebec, and Thunder Bay, Ontario.

Certain statements contained in this news release are forward-looking and are subject to numerous risks and uncertainties, known and unknown. For information identifying known risks and uncertainties, relating to financial resources, liquidity risk, key customers and business partners, credit risk, foreign currency risk, government regulations, laboratory facilities, volatility of share price, employees, suppliers, and other important factors that could cause actual results to differ materially from those anticipated in the forward-looking statements, please refer to the heading Risks and Uncertainties in Warnex's most recent Management's Discussion and Analysis, which can be found at Consequently, actual results may differ materially from the anticipated results expressed in these forward-looking statements.

Back to press releases list